sandrock said futility analysis happened soon looked data based december trials actually stopped march biogen run studies positive right high dose second failed shows signs benefit patients received higher dose aducanumab situation highly unusual sandrock said fda decide approve drug based single positive trial said biogen met fda twice discuss decision june monday said fda provided preliminary written comments led biogen file approval biogen moved forward announcement waiting meeting minutes surprises meeting sandrock quietly sharing data outside experts people initial skepticism said rightly start data excited prospect drug approved biogen presented new data alzheimer trial conference wall street analysts grappled